Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

Shares of Legend Biotech (NASDAQ:LEGN) are climbing 6% to $21.88 Tuesday midday aft the institution reported Q2 2026 results that paired a coagulated gross bushed with the archetypal 4th of company-wide profitability successful its history. LEGN banal is inactive down 41% implicit the past year, truthful today's absorption reads arsenic validation of Legend Biotech's CARVYKTI ramp.

Legend Biotech disclosed the results successful an SEC filing earlier the unfastened and hosted its net telephone astatine 8:00 a.m. ET. The commercialized trajectory of CARVYKTI, the CAR-T aggregate myeloma therapy Legend co-develops with Johnson & Johnson (NYSE:JNJ) done its Janssen unit, continues to anchor the concern lawsuit here.

The setup entering the study was dense for Legend Biotech. LEGN banal had drifted little done July, and short-dated positioning had grown cautious astir the ongoing CEO transition, leaving country for a compression connected immoderate cleanable numbers.

Revenue Beat and a First Profitable Quarter

Legend Biotech posted full gross of $387.5 million, up 52% twelvemonth implicit year, topping the $362.81 cardinal estimate. Legend Biotech's adjusted EPS came successful astatine $0.16, much than treble the astir $0.07 expert consensus. The gross bushed headlined the report, though the bigger astonishment sat further down the income statement.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Legend Biotech didn't marque the cut. Grab the names FREE today.

Legend Biotech booked nett income of $33.2 cardinal versus a nett nonaccomplishment of $125.4 cardinal a twelvemonth earlier, adjusted nett income of $63.1 million, and operating income of $57.7 million. That marks the company's archetypal 4th of company-wide profitability connected some an IFRS and adjusted basis.

A meaningful portion of the plaything reflects overseas speech dynamics for Legend Biotech. Unrealized FX losses fell to $0.6 cardinal successful Q2 2026 from $110.9 cardinal a twelvemonth earlier, cushioning the bottommost enactment adjacent arsenic operating gains did astir of the work.